Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
29 Jun, 2021 | 10:09h | UTCInvited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases
Commentary on Twitter
NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc
— The Lancet (@TheLancet) June 28, 2021